成纤维细胞生长因子受体（FGFR）抑制剂是一类新兴的小分子靶向癌症药物，对于多种恶性肿瘤具有潜在的治疗可能性。虽然临床试验中报告了 FGFR 抑制剂引起的眼部不良事件，但随后的案例研究继续揭示新的毒性。影响眼睛多个部位的疾病病理学已有报道，但眼表和视网膜是最常受 FGFR 抑制剂影响的区域，分别表现为干眼和 FGFR 抑制剂相关性视网膜病变。角膜变薄和融化是 FGFR 抑制剂毒性的一种罕见但严重且可能威胁视力的并发症。其他靶向癌症治疗药物和 FGFR 抑制剂观察到的毒性之间的相似性可能有助于我们了解潜在的病理生理变化。这些不良事件的管理需要密切的眼科随访，并且在某些情况下可能需要停止使用违规药物。版权所有 © 2023 Elsevier Inc. 保留所有权利。

Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer drugs with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in clinical trials, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye have been reported, but the ocular surface and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy, respectively. Corneal thinning and melt is a rare but serious and potentially vision threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases.Copyright © 2023 Elsevier Inc. All rights reserved.